Drug intelligence / Profile preview

JYP0061

Development stage: Phase 2
Lead developer: Guangzhou JOYO Pharma Co., Ltd
Modality: Small Molecules
Administration: Oral

Overview

JYP0061 is an orally administered small molecule drug candidate under development for the treatment of autoimmune and inflammatory diseases, including moderate-to-severe atopic dermatitis and neuromyelitis optica spectrum disorder (NMOSD). It is being developed by Guangzhou JOYO Pharma (also referred to as Guangzhou Jiayue Pharmaceutical Technology). The precise mechanism of action has not been disclosed or defined in public sources. Clinical trials are ongoing in China, with Phase 2 studies recruiting for both atopic dermatitis and NMOSD. In these trials, JYP0061 is evaluated as monotherapy or in combination with glucocorticoids. There are no approved indications or known adverse events reported to date[1][2][4][6].

Other names: JYP-0061JYP0061JYP 0061

Beyond the preview

Go deeper on JYP0061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JYP0061.

Explore the full profile